{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:14:09Z","timestamp":1786115649001,"version":"build-2736575974"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endocrine complications after chimeric antigen receptor (CAR) T-cell therapy remain poorly characterized. Thyroid dysfunction is well recognized during immune checkpoint inhibitor therapy, but thyroid function is not routinely incorporated into post-CAR T-cell toxicity assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After observing an index case of destructive thyroiditis after CAR T-cell therapy, scheduled thyroid function monitoring was implemented in the subsequent 94 consecutive CAR T-cell recipients at our institution. This single-center study therefore included the index case and 94 consecutive post-index patients treated with axicabtagene ciloleucel, lisocabtagene maraleucel, or idecabtagene vicleucel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two patients developed transient thyrotoxicosis compatible with destructive thyroiditis, corresponding to an observed proportion of 2 of 95 patients [2.1%; exact 95% confidence interval (CI), 0.3\u20137.4%]. Both cases occurred among the 12 patients who experienced grade \u22652 cytokine release syndrome (CRS; 2 of 12; exact 95% CI, 2.1\u201348.4%). One case was supported by markedly reduced uptake on thyroid scintigraphy, whereas the other was considered probable destructive thyroiditis. Minor or transient thyroid function abnormalities that did not meet the diagnostic criteria for destructive thyroiditis were also observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Destructive thyroiditis may occur after CAR T-cell therapy and may be underrecognized because its manifestations overlap with other post-CAR T-cell inflammatory toxicities. The occurrence of both cases after grade \u22652 CRS represents a possible association and should be considered hypothesis-generating.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1876913","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:25:26Z","timestamp":1785990326000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-CAR T-cell thyroid dysfunction: destructive thyroiditis identified through thyroid function monitoring in a single-center cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Yoshiyuki","family":"Fujita","sequence":"first","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]},{"name":"Department of Transfusion Medicine and Cellular Therapy, Hyogo Medical University Hospital","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuto","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuki","family":"Yamagata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kumamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Samori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuji","family":"Kaida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazuko","family":"Tokugawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Higasa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]},{"name":"Department of Transfusion Medicine and Cellular Therapy, Hyogo Medical University Hospital","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Medical University School of Medicine","place":["Nishinomiya, Japan"]},{"name":"Department of Transfusion Medicine and Cellular Therapy, Hyogo Medical University Hospital","place":["Nishinomiya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac689","article-title":"Approach to the patient with immune checkpoint inhibitor-associated endocrine dysfunction","volume":"108","author":"Wright","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101158","article-title":"Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells","volume":"4","author":"Strati","year":"2023","journal-title":"Cell Rep Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995496","article-title":"Case report: Hashimoto's thyroiditis after CD19 chimeric antigen receptor T-cell therapy","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/39.8.1739","article-title":"Factitious hyperthyroxinemia due to a monoclonal IgA in a case of multiple myeloma","volume":"39","author":"Cissewski","year":"1993","journal-title":"Clin Chem"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876913\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:25:27Z","timestamp":1785990327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876913\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":9,"alternative-id":["10.3389\/fonc.2026.1876913"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1876913","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1876913"}}